Latest:
Imlunestrant With/Without Abemaciclib Maintains PFS, OS Benefit in ER+/HER2– Breast Cancer
Imlunestrant alone or in combination with abemaciclib significantly improved PFS in ER-positive and HER2-negative breast cancer.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Jason M. Wallen, MD, MBA, FACS, FCCP
Latest:
Dr. Wallen on Surgery in Patients With Advanced Lung Cancer
Jason M. Wallen, MD, MBA, FACS, FCCP, associate professor of surgery, division chief of thoracic surgery, director of gastric and esophageal cancer program, medical director of the thoracic oncology program, Upstate University Hospital, discusses the role of surgery in patients with advanced-stage lung cancer.
Jason Matney, PhD
Latest:
Jason Matney on Deep Inspiration Breath Hold During Radiation Therapy for Breast Cancer
Jason Matney, PhD, clinical assistant professor, Physics and Computing Division, Department of Radiation Oncology, UNC School of Medicine, discusses a prospective assessment of deep inspiration breath hold to prevent radiation-associated cardiac perfusion defects in patients with left-sided breast cancer.
Jason Westin, MD, MS, FACP, MD Anderson Cancer Center
Latest:
Diffuse Large B-Cell Lymphoma: Unmet Needs and Future Directions in Care
Closing out their discussion on the management of relapsed/refractory diffuse large B-cell lymphoma, expert panelists highlight unmet needs and share excitement for future evolutions in the treatment landscape.
Javier Pinilla, MD, PhD
Latest:
Catching Up on the Latest Data in CLL and Lymphoma With Drs Emmons, Brody, and Pinilla
Robert Emmons, MD, FACP, Joshua Brody, MD, and Javier Pinilla, MD, PhD, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in chronic lymphocytic leukemia and lymphoma presented during the 2025 ASH Annual Meeting & Exposition.